Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139446 | 0.82 | SLC5A1 (0.51) | SLC5A2SLC5A1MPOKDM1AKDM1B | |
| SCHEMBL20140227 | 0.79 | SLC5A1 (0.53) | SLC5A2SLC5A1ALDH1A1MAPT | |
| SCHEMBL16682942 | 0.79 | SNCA (0.47) | SLC5A2SLC5A1MPOHPGDCYP1A2 | |
| SCHEMBL20139367 | 0.77 | SLC5A2 (0.48) | SLC5A2SLC5A1MPOHPGDALDH1A1 | |
| SCHEMBL20140091 | 0.74 | SLC5A1 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL20139495 | 0.69 | HTR2A (0.42) | SLC5A2SLC5A1KDM1A | |
| SCHEMBL20140121 | 0.69 | NPC1 (0.41) | HPGDALDH1A1CYP1A2MAPTCYP2C19 | |
| SCHEMBL28490129 | 0.68 | KDM1A (0.38) | KDM1AKDM1B | |
| SCHEMBL16682980 | 0.67 | GRIN2B (0.35) | HPGDCYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL20139399 | 0.67 | SLC5A2 (0.42) | SLC5A2SLC5A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885MPO 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.